Gritstone's candidate is a self-amplifying messenger RNA vaccine (samRNA), which uses a slightly different technology to the mRNA-based jabs from Pfizer/BioNTech and Moderna.
This is a summary of a request from Gritstone bio to hire Fenwick & West as special corporate counsel, filed Oct. 23 with the U.S. Bankruptcy Court in Delaware.
Gritstone bio, Inc. (NASDAQ:GRTS), a biotechnology company, has disclosed a significant reduction in its workforce and the impending delisting of its common stock from the Nasdaq Stock Market.
生物技术公司Gritstone bio, Inc. (NASDAQ:GRTS)已披露其将大幅裁减员工并即将从纳斯达克证券交易所摘牌。该专门从事生物制品的公司宣布,将在2024年11月15日前裁减约25名员工,相当于其总员工的19%,保留约101名员工。这一决定是公司在第11章破产程序中重组运营的一部分 ...